HIGH Stock Overview
Operates as a medical cannabis company in Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cantourage Group SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.50 |
| 52 Week High | €11.00 |
| 52 Week Low | €4.12 |
| Beta | -0.38 |
| 11 Month Change | -1.32% |
| 3 Month Change | -12.62% |
| 1 Year Change | -44.65% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.39% |
Recent News & Updates
Shareholder Returns
| HIGH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -10.1% | -1.5% |
| 1Y | -44.6% | -21.6% | 7.9% |
Return vs Industry: HIGH underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: HIGH underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| HIGH volatility | |
|---|---|
| HIGH Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HIGH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HIGH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 625 | Philip Schetter | www.cantourage.com |
Cantourage Group SE operates as a medical cannabis company in Europe. It offers dried flowers, extracts, dronabinol products, and pharma-grade cannabidiol products. The company was founded in 2019 and is based in Kleinmachnow, Germany.
Cantourage Group SE Fundamentals Summary
| HIGH fundamental statistics | |
|---|---|
| Market cap | €53.87m |
| Earnings (TTM) | €221.14k |
| Revenue (TTM) | €1.96m |
253.8x
P/E Ratio28.6x
P/S RatioIs HIGH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIGH income statement (TTM) | |
|---|---|
| Revenue | €1.96m |
| Cost of Revenue | €0 |
| Gross Profit | €1.96m |
| Other Expenses | €1.74m |
| Earnings | €221.14k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 100.00% |
| Net Profit Margin | 11.27% |
| Debt/Equity Ratio | 0% |
How did HIGH perform over the long term?
See historical performance and comparison